Research focuses on chronic myeloid leukemia with the goal of creating a new therapy for patients Study funded by Robert & Lynda Carter Altman Family Foundation Research Fund LOS ANGELES--(BUSINESS ...

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...

Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the ...

Although mild leukocytosis is common in pregnancy, markedly elevated counts warrant prompt evaluation to exclude pathological causes such as infections and leukaemia. Chronic myeloid leukaemia (CML) ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...

Please provide your email address to receive an email when new articles are posted on . Jorge Cortes, MD, received Society of Hematologic Oncology’s Michael J. Keating Outstanding Achievement Award.

If the name of leukemia specialist Jorge Cortes, MD, appears any more often in PubMed, they’ll need to name a wing after him. Jorge Cortes, MD Over 30 years, Cortes has led or co-authored hundreds of ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

CML and the WHO: Why? The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are ...